Universe Pharmaceuticals INC
UPC · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D49China-based TCM maker with declining revenue, persistent net losses, and material PRC-governance risk.
Strengths
- Healthy liquidity with current ratio 4.07 and quick ratio 3.90 (~55th pct)
- Narrowing net loss ($3.7M vs $8.7M prior year) and recognized regional brands
Risks
- Revenue down ~22% with own-product and third-party sales both falling; net margin -20.6% and FCF deeply negative
- Gross margin 35% (18th pct) plus PRC regulatory/governance overhang and no product-liability insurance
Notable findings
- No interest coverageInterest coverage -10.08 (cannot cover interest)
- Net lossNet loss (net margin -20.6%)
- Cash burnNegative free cash flow (-5319.1M)
- Revenue declineRevenue -22.4% YoY
Key metrics
Gross margin
35.3%
Operating margin
-16.3%
Net margin
-20.6%
Return on equity
-6.5%
Return on assets
-5.3%
Revenue growth (QoQ)
-22.4%
Interest coverage
-10.1×
Current ratio
4.1×
Free cash flow
-$5.3B
EBITDA
-$2.4B
Tangible book value
$55.8B
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-07 | Lai Gang | Grant | 72K | — |
| 2026-05-07 | Lai Gang | Grant | 13K | — |
All non-derivative Form 4 activity (SEC), newest first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-01-29 | 2025-09-30 | 0001213900-26-009000 ↗ |
| 20-F | 2025-04-29 | 2024-09-30 | 0001213900-25-036798 ↗ |
| 20-F | 2024-01-30 | 2023-09-30 | 0001213900-24-007745 ↗ |
| 20-F | 2023-02-10 | 2022-09-30 | 0001213900-23-010349 ↗ |
| 20-F | 2022-01-31 | 2021-09-30 | 0001213900-22-004359 ↗ |